↓ Skip to main content

Dove Medical Press

Article Metrics

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability

Overview of attention for article published in Pharmacogenomics and Personalized Medicine, December 2014
Altmetric Badge

Mentioned by

blogs
1 blog
twitter
1 tweeter
patent
2 patents

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
55 Mendeley
Title
Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
Published in
Pharmacogenomics and Personalized Medicine, December 2014
DOI 10.2147/pgpm.s52629
Pubmed ID
Authors

Warren Schmidt, Zeid Kayali

Abstract

Chronic Hepatitis C virus (HCV) infection is the leading cause of advanced liver disease worldwide. The virus successfully evades host immune detection and for many years has hampered efforts to find a safe, uncomplicated, and reliable oral antiviral therapy. Initially, interferon and ribavirin therapy was the treatment standard of care, but it offered limited performance across the wide spectrum of HCV disease and was fraught with excessive and often limiting side effects. Sofosbuvir (SOF) is a potent first-in-class nucleoside inhibitor that has recently been approved for treatment of HCV. The drug has low toxicity, a high resistance barrier, and minimal drug interactions with other HCV direct-acting antiviral agents such as protease inhibitors or anti-NS5A agents. SOF is safe and can be used across different viral genotypes, disease stages, and special patient groups, such as those coinfected with human immunodeficiency virus. When used in combination with ribavirin or another direct-acting antiviral agent, SOF has revolutionized the HCV treatment spectrum and set the stage for nearly universal HCV antiviral therapy. More so than any other anti-HCV drug developed to date, SOF offers the widest applicability for all infected patients, and new regimens will be tailored to maximize performance.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
India 1 2%
Egypt 1 2%
Unknown 52 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 14 25%
Student > Master 12 22%
Student > Ph. D. Student 7 13%
Researcher 5 9%
Student > Doctoral Student 3 5%
Other 11 20%
Unknown 3 5%
Readers by discipline Count As %
Medicine and Dentistry 18 33%
Agricultural and Biological Sciences 12 22%
Biochemistry, Genetics and Molecular Biology 5 9%
Immunology and Microbiology 4 7%
Chemistry 3 5%
Other 8 15%
Unknown 5 9%